Peptide Profile
ARA-290 (Cibinetide)
ARA-290, also known generically as Cibinetide, is a synthetic 11-amino-acid peptide engineered from the helix B surface domain of human erythropoietin (EPO).
1. Chemical Structure and Biochemistry
ARA-290 is a non-hematopoietic EPO analogue.
- Peptide Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- Structural Modification: The peptide is specifically truncated and modified (featuring an N-terminal pyroglutamate) to separate the tissue-protective properties of EPO from its blood-building properties, bypassing the classical EPO receptor that causes cardiovascular risks at high doses.
2. Mechanism of Action
ARA-290 specifically targets the Innate Repair Receptor (IRR), a heteromeric complex comprised of the EPO receptor (EPOR) and the beta-common receptor (CD131).
- Anti-inflammatory: Activation of the IRR turns off the production of pro-inflammatory cytokines (like TNF-alpha) by macrophages.
- Tissue Repair: Stimulates the healing and survival of cells subjected to stress, hypoxia, or injury.
3. Research and Applications
The peptide has been a major focus in clinical research regarding neuropathic pain and immune-mediated diseases.
- Neuropathy & Nerve Repair: Heavily researched for small fiber neuropathy, particularly in patients with Type 2 Diabetes or Sarcoidosis, showing potential to promote nerve fiber regrowth.
- Autoimmune & Inflammatory Conditions: Explored for treating conditions involving chronic systemic inflammation.
Tags:
ARA-290
Cibinetide
helix-B-surface-peptide
Innate-Repair-Receptor
IRR
erythropoietin-analogue
non-hematopoietic-EPO
neuropathy
nerve-repair
sarcoidosis
anti-inflammatory-peptide